Software in the real world: "How many bugs do you have?"
This article was originally published in Clinica
Executive Summary
Medical device software is often cited as a source of problems in real use by both regulators and manufacturers. Many companies lack a structured approach to software development and often end up fixing "bugs" the expensive way - in the field. But with planning and modest outlay in the design and development stage, many costly problems can be avoided. Tools that make this easier are now emerging, says medical device industry consultant Trevor Lewis, who also suggests that companies learn to use the methods and tools developed in the US and other industries.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.